FEV1 · patients with chronic obstructive pulmonary disease
1 finding from 1 review
FEV1 pre‐dose ‐ FEV1 1 year · patients with chronic obstructive pulmonary disease
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Moderate
Vasomotor symptoms (all doses) · postmenopausal women with vasomotor symptoms
Tibolone probably leads to lower vasomotor symptoms (all doses) compared with placebo (moderate certainty).
1 finding from 1 review
Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone probably leads to lower unscheduled bleeding (all doses) compared with combined HT (moderate certainty).
1 finding from 1 review
Endometrial cancer · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation; all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Cardiovascular events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cardiovascular events (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cerebrovascular event (all doses) compared with combined HT (very low certainty).
1 finding from 1 review
Mortality from any cause (tibolone 2.5 mg/d) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes mortality from any cause (tibolone 2.5 mg/d) compared with combined HT (very low certainty).
1 finding from 1 review
Endometrial cancer · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes endometrial cancer (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Breast cancer; women without previous breast cancer (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes breast cancer; women without previous breast cancer (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Unscheduled bleeding (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone probably leads to higher unscheduled bleeding (all doses) compared with placebo (moderate certainty).
1 finding from 1 review
Venous thromboembolic events · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes venous thromboembolic events (clinical evaluation) all doses compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular events · postmenopausal women with or without vasomotor symptoms
1 finding from 1 review
Cerebrovascular event (all doses) · postmenopausal women with or without vasomotor symptoms
It is very uncertain whether tibolone changes cerebrovascular events (all doses) compared with placebo (very low certainty).
1 finding from 1 review
Mortality from any cause (all doses) · postmenopausal women with or without vasomotor symptoms
Tibolone showed no clear difference in mortality from any cause (all doses) compared with placebo (low certainty).
1 finding from 1 review
Vasomotor symptoms (tibolone 2.5 mg/d) · postmenopausal women with vasomotor symptoms
Tibolone probably leads to higher vasomotor symptoms (tibolone 2.5 mg/d) compared with combined HT (moderate certainty).
1 finding from 1 review
Intervention not reported
Behavioural outcome: immunisation rate ATCS Plus, IVR, unidirectional versus no calls, letters, usual care at median · participants at risk of under‐immunisation (children, adolescents and adults)
The intervention probably leads to higher behavioural outcome: immunisation rate ATCS Plus, IVR,… (moderate certainty).
1 finding from 1 review
Intervention not reported
Behavioural outcome: breast cancer screening Multimodal/complex intervention versus usual care at 12 months · participants at risk for breast, colorectal or cervical cancer; or osteoporosis
The intervention leads to higher behavioural outcome: breast cancer screening Multimodal/complex… (high certainty).
1 finding from 1 review